

**Title of the Clinical Trial:** Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma (H11), a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group.

**Sponsor:** European Organisation for Research and Treatment of Cancer (EORTC)

**EORTC protocol number:** 20101-23101

**EudraCT number:** 2011-005473-22

**Protocol:** version 2.1 dated June 22, 2010

**Concerning:** Premature end of trial.

Dear madam/sir,

EORTC Study 20101-23101 has been discontinued before any enrolment of patients. All efforts made by the EORTC to find a solution to continue this study in a different setting were unsuccessful, due to many factors.

The rationale to this unfortunate decision is exposed in the enclosed letter from Dr Roger Stupp, President of the EORTC at the time of study closure. The letter was addressed to Dr Martin Hutchings, study coordinator, on 06 March 2014.

We also confirm hereby that at present no patients were ever screened, randomised or treated.

Please note that all participating Investigators / sites have been informed about this premature end of trial by the sponsor.

Yours sincerely,  
EORTC Headquarters

